NDRA — ENDRA Life Sciences Balance Sheet
0.000.00%
- $5.35m
- $4.21m
Annual balance sheet for ENDRA Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | C2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-Q | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 6.17 | 7.23 | 9.46 | 4.89 | 2.83 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 6.54 | 8.21 | 12.1 | 5.38 | 3.03 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.641 | 0.551 | 0.775 | 0.741 | 0.466 |
Other Long Term Assets | |||||
Total Assets | 7.18 | 8.76 | 12.9 | 9.27 | 6.75 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 2.07 | 0.987 | 1.54 | 1.7 | 0.903 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.42 | 1.6 | 2.09 | 2.07 | 1.1 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 4.76 | 7.17 | 10.8 | 7.2 | 5.66 |
Total Liabilities & Shareholders' Equity | 7.18 | 8.76 | 12.9 | 9.27 | 6.75 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |